Literature DB >> 11378378

Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.

A D Baxter1, R Bhogal, J Bird, J F Keily, D T Manallack, J G Montana, D A Owen, W R Pitt, R J Watson, R E Wills.   

Abstract

A series of novel matrix metalloproteinase inhibitors is described in which selectivity between MMP and 'sheddase' activity has been achieved and which demonstrate potent in vivo activity in models of arthritis and cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378378     DOI: 10.1016/s0960-894x(01)00259-1

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  L-selective amidase with extremely broad substrate specificity from Ochrobactrum anthropi NCIMB 40321.

Authors:  Theo Sonke; Sandra Ernste; Renate F Tandler; Bernard Kaptein; Wilco P H Peeters; Friso B J van Assema; Marcel G Wubbolts; Hans E Schoemaker
Journal:  Appl Environ Microbiol       Date:  2005-12       Impact factor: 4.792

Review 2.  Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.

Authors:  Vanessa J Craig; Li Zhang; James S Hagood; Caroline A Owen
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

Review 3.  The ADAMTS metalloproteinases.

Authors:  Sarah Porter; Ian M Clark; Lara Kevorkian; Dylan R Edwards
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

4.  An E/Z conformational behaviour study on the trypanocidal action of lipophilic spiro carbocyclic 2,6-diketopiperazine-1-acetohydroxamic acids.

Authors:  Alexandra Tsatsaroni; Grigoris Zoidis; Panagiotis Zoumpoulakis; Andrew Tsotinis; Martin C Taylor; John M Kelly; George Fytas
Journal:  Tetrahedron Lett       Date:  2013-06-19       Impact factor: 2.415

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.